tradingkey.logo
搜索

Anika Therapeutics Inc

ANIK
添加自选
19.250USD
+1.180+6.53%
收盘 07-31 16:00美东报价延迟15分钟
257.12M总市值
亏损市盈率 TTM

关于 Anika Therapeutics Inc 公司

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Anika Therapeutics Inc简介

公司代码ANIK
公司名称Anika Therapeutics Inc
上市日期May 16, 1985
CEOBlanchard (Cheryl Renee)
员工数量288
证券类型Ordinary Share
年结日May 16
公司地址32 Wiggins Ave
城市BEDFORD
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01730-2315
电话17814579000
网址https://anika.com/
公司代码ANIK
上市日期May 16, 1985
CEOBlanchard (Cheryl Renee)

Anika Therapeutics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
52.97K
+19.64%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
30.80K
+33.77%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Susan L. N. Vogt
Ms. Susan L. N. Vogt
Independent Director
Independent Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Stephen O. Richard
Mr. Stephen O. Richard
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
52.97K
+19.64%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
30.80K
+33.77%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

常见问题

Anika Therapeutics Inc的前五大股东是谁?

Anika Therapeutics Inc 的前五大股东如下:Mr. Stephen D. (Steve) Griffin

有多少机构持有Anika Therapeutics Inc(ANIK)的股份?

截至2026Q1,共有264家机构持有Anika Therapeutics Inc的股份,合计持有的股份价值约为12.85M,占公司总股份的96.55%。与2025Q4相比,机构持股有所增加,增幅为-1611291.00。

哪个业务部门对Anika Therapeutics Inc的收入贡献最大?

在2026Q1,OEM Channel业务部门对Anika Therapeutics Inc的收入贡献最大,创收64.41M,占总收入的57.09%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有